Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alterity Therapeutics ( (ATHE) ) has provided an update.
Alterity Therapeutics announced on February 17, 2025, the issuance of 1,165,841,830 fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act. This issuance, compliant with the relevant provisions of the Corporations Act, indicates Alterity’s strategic maneuver to potentially bolster its capital structure, influencing its operational capability and market positioning.
More about Alterity Therapeutics
Alterity Therapeutics Limited operates in the biotechnology industry, focusing on the development of therapeutic products. The company is primarily engaged in research and development to address neurodegenerative diseases, with a market focus on diseases such as Alzheimer’s and Parkinson’s.
YTD Price Performance: 18.50%
Average Trading Volume: 531,051
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $42.22M
For an in-depth examination of ATHE stock, go to TipRanks’ Stock Analysis page.